EUCTR2019-000642-35-BG进行中（未招募）1 期
A phase IIa randomized, double-blind, multicentre study to evaluate safety and efficacy of HL217 topical ophthalmologic solution in the treatment of exudative Age-Related Macular Degeneration (AMD)
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male and menopaused women patients, aged 50 years or more;
- •2. Active subfoveal choroidal neovascularization (CNV) due to Age-related Macular Degeneration (AMD) in the study eye diagnosed using fluorescein and if available with indocyanine green angiography and SD-OCT, total lesion =12 Macular Photocoagulation Study (MPS) disc areas or =30,48 mm², with the active lesion (excluding fibrosis and subretinal hemorrhage) should be =50% of the total lesion size.
- •3. Intraretinal or subretinal fluid due to choroidal neovascularization (CNV) visible on SD-OCT;
- •4. Best-corrected Visual Acuity (BCVA) between 78 and 14 letters, inclusive, in the study eye at the screening/randomization visit using Early Treatment Diabetic Retinopathy Study (ETDRS) testing, with BCVA decrement primarily attributable to neovascular Age-related Macular Degeneration (AMD);
- •5. Treatment naive (i.e., no previous anti-vascular endothelial growth factor [VEGF] treatment in the study eye);
- •6. Media clarity, pupillary dilation, and subject cooperation sufficient for adequate fundus imaging;
- •7. Willing and able to return for all study visits;
- •8. Able to adhere to the study protocol and its requirements;
- •9. Signing a written informed consent prior to selection;
- •10. Covered by Health Insurance System and / or in compliance with the recommendations of National Law in force relating to biomedical research.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 90
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 90
排除标准
- •1. Non-study eye best corrected visual acuity (BCVA) worse than 20 letters at the screening/randomization visit using Early Treatment Diabetic Retinopathy Study (ETDRS) testing;
- •2. Choroidal neovascularization (CNV) in the study eye with either major atrophy and no possible vision recovery, or ocsecondary to other causes (e.g., pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, posterior uveitis, or multifocal choroiditis);
- •3. Polypoidal choroidal vasculopathy (PCV). The diagnosis of PCV required either the presence of elevated orange-red lesions observed at the fundus or the presence of characteristic polypoidal vascular lesions by ICGA;
- •4. Previous macular laser photocoagulation or ocular photodynamic therapy in the study eye;
- •5. Media opacities or abnormalities in the study eye that would preclude visualization of the retina;
- •6. Other retinal diseases in the study eye that would interfere with vision; including: retinal pigment epithelial (RPE) tear, subretinal haemorrhage (including the fovea);
- •7. Uncontrolled glaucoma or ocular hypertension in the study eye defined as an Intraocular Pressure (IOP) > 25 millimeters of mercury (mmHg) regardless of concomitant treatment with IOP lowering medications;
- •8. Previous pars plana vitrectomy in the study eye;
- •9. Any intraocular surgery in the study eye within 90 days (3 months) prior to study enrolment;
- •10. Yttrium aluminium garnet (YAG) laser treatment in the study eye within 30 days (1 month) prior to study enrolment;
- •11. Intravitreal/periocular ocular steroids (dexamethasone implant or triamcinolone injection) in the study eye within 90 days (3 months) prior to study enrolment;
- •12. Topical or subconjunctival injection of steroid (except triamcinolone) in the study eye within 15 days;
- •13. Concomitant use of any topical ophthalmic medications in the study eye, including glaucoma medications, unless on a stable dose for at least 90 days (3 months) prior to study enrolment and expected to stay on stable dose throughout study participation. Artificial tears are allowed but not ointments;
- •14. Chronic or recurrent uveitis in the study eye;
- •15. Ongoing ocular infection or inflammation in either eye, suspected ocular infection and active or suspected periocular infection;
- •16. A history of cataract surgery complicated by vitreous loss in the study eye;
- •17. Congenital eye malformations in the study eye;
- •18. A history of penetrating ocular trauma in the study eye;
- •19. Any history of clinically significant vascular disease, and any personal or family history of long QT syndrome, or evidence of abnormalities in cardiac conduction or electrolyte disturbance;
- •20. Patient with high thromboembolic risk
- •21. Hypersensitivity to the active substance aflibercept or to any of the excipients;
- •22. Patient under administrative or legal supervision;
- •23. Females of childbearing potential (i.e., who are not postmenopausal for at least 1 year or surgically sterile like hysterectomy, bilateral salpingectomy and bilateral oophorectomy for at least 6 weeks prior to Visit 1 - Screening/Randomization) who are lactating, or who are pregnant as determined by a positive urine pregnancy test (UPT) at Visit 1 - Screening/Randomization;
- •24. Participation in any other investigational device or drug clinical research study within 30 days of Visit 1 - Screening/Randomization.
研究者
相似试验
进行中（未招募）
1 期
A phase IIa randomized, double-blind, multicentre study to evaluate safety and efficacy of HL217 topical ophthalmologic solution in the treatment of exudative Age-Related Macular Degeneration (AMD)AMD (age-related macular degeneration)MedDRA version: 20.0Level: LLTClassification code 10068530Term: Macular degeneration progressionSystem Organ Class: 100000004853EUCTR2019-000642-35-FRHANLIM PHARM CO., LTD78
进行中（未招募）
1 期
A phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with seasonal surface antigen, inactivated, adjuvanted influenza vaccine (SIIV) in adults older than 65 years of age fully vaccinated against COVID-19.SARS-CoV-2 and InfluenzaCTIS2023-506189-29-00Hipra Scientific S.L.300
进行中（未招募）
不适用
A phase II, double-blind, randomized, multi-center, adaptive dose-ranging, placebo-controlled, parallel-group study evaluating safety, tolerability and efficacy on MRI lesion parameters and determining the dose response curve of BAF312 given orally once daily in patients with relapsingremitting multiple sclerosis - NDMedDRA version: 9.1Level: LLTClassification code 10028245Term: Multiple sclerosismultiple sclerosisEUCTR2008-008719-25-ITOVARTIS FARMA275
进行中（未招募）
不适用
A phase II, double-blind, randomized, multi-center, adaptive dose-ranging, placebo-controlled, parallel-group study evaluating safety, tolerability and efficacy on MRI lesion parameters and determining the dose response curve of BAF312 given orally once daily in patients with relapsing-remitting multiple sclerosisRelapsing-remitting multiple sclerosisMedDRA version: 9.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisEUCTR2008-008719-25-FIovartis Pharma Services AG275
进行中（未招募）
不适用
A phase II, double-blind, randomized, multi-center, adaptive dose-ranging, placebo-controlled, parallel-group study evaluating safety, tolerability and efficacy on MRI lesion parameters and determining the dose response curve of BAF312 given orally once daily in patients with relapsing-remitting multiple sclerosisRelapsing-remitting multiple sclerosisMedDRA version: 9.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisEUCTR2008-008719-25-DEovartis Pharma Services AG275